Ken Griffin Oncorus, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.28 - $0.45 $25,004 - $40,185
-89,300 Reduced 95.61%
4,100 $1,000
Q4 2022

Feb 14, 2023
BUY
$0.24 - $0.76 $480 - $1,520
2,000 Added 2.19%
93,400 $23,000
Q3 2022

Nov 14, 2022
SELL
$0.85 - $1.65 $81,260 - $157,740
-95,600 Reduced 51.12%
91,400 $78,000

About Oncorus, Inc.

ONCR Quotes by TradingView
  • Ticker ONCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,973,100
  • Description
  • Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...
More about ONCR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email